Key Takeaways
- Graph Therapeutics raised $5.0M (Series C) from Daphni, SquareOne, Merantix Capital, NAVEC.
- Sector: Biotechnology & Life Sciences, Healthcare, Healthtech & Medtech.
- Geography: Austria.
Analysis
- Graph Therapeutics, a biotech company based in Klosterneuburg, Austria, has secured a significant investment.
- The funding round was led by Daphni, with participation from SquareOne, Merantix Capital, and NAVEC.
- This $5 million investment brings the total funding for Graph Therapeutics to over $10 million, including grants from FFG and AWS.
- The investment will likely fuel further development and expansion of Graph Therapeutics' operations in the biotechnology sector.